Future strategies for preventing and treating coronary restenosis

Ehrin J. Armstrong; John C. Messenger

Future strategies for preventing and treating coronary restenosis

Ehrin J. Armstrong, John C. Messenger

Research output: Chapter in Book/Report/Conference proceeding › Chapter

Abstract

While drug-eluting stents have improved outcomes after percutaneous coronary intervention, 4-14% of patients in modern clinical trials still develop symptomatic restenosis. Future strategies for prevention of restenosis include modifications to the stent platform, the drug polymer or drug elution system, biocompatible stent coatings, use of bioresorbable scaffolds, and optimization of local and systemic anti-restenotic agents. Novel approaches to treating restenosis include a number of ongoing trials comparing treatment strategies with currently available drug eluting stents, use of drug coated balloons, and interventional strategies to increase stent expansion. While no single technology is likely to eliminate restenosis, the combination of these prevention and treatment strategies promises to improve the long-term outcomes of percutaneous coronary intervention.

Original language	English (US)
Title of host publication	Coronary Artery Restenosis: Causes, Treatment and Clinical Outcomes
Publisher	Nova Science Publishers, Inc.
Pages	263-283
Number of pages	21
ISBN (Electronic)	9781633213531
ISBN (Print)	9781633213463
State	Published - Jan 1 2014
Externally published	Yes

ASJC Scopus subject areas

Medicine(all)

Access to Document

Fingerprint Dive into the research topics of 'Future strategies for preventing and treating coronary restenosis'. Together they form a unique fingerprint.

Cite this

Armstrong, E. J., & Messenger, J. C. (2014). Future strategies for preventing and treating coronary restenosis. In Coronary Artery Restenosis: Causes, Treatment and Clinical Outcomes (pp. 263-283). Nova Science Publishers, Inc..

@inbook{32adad29f7994442b2a033381f0ca6af,

title = "Future strategies for preventing and treating coronary restenosis",

abstract = "While drug-eluting stents have improved outcomes after percutaneous coronary intervention, 4-14% of patients in modern clinical trials still develop symptomatic restenosis. Future strategies for prevention of restenosis include modifications to the stent platform, the drug polymer or drug elution system, biocompatible stent coatings, use of bioresorbable scaffolds, and optimization of local and systemic anti-restenotic agents. Novel approaches to treating restenosis include a number of ongoing trials comparing treatment strategies with currently available drug eluting stents, use of drug coated balloons, and interventional strategies to increase stent expansion. While no single technology is likely to eliminate restenosis, the combination of these prevention and treatment strategies promises to improve the long-term outcomes of percutaneous coronary intervention.",

author = "Armstrong, {Ehrin J.} and Messenger, {John C.}",

year = "2014",

month = jan,

day = "1",

language = "English (US)",

isbn = "9781633213463",

pages = "263--283",

booktitle = "Coronary Artery Restenosis: Causes, Treatment and Clinical Outcomes",

publisher = "Nova Science Publishers, Inc.",

}

TY - CHAP

T1 - Future strategies for preventing and treating coronary restenosis

AU - Armstrong, Ehrin J.

AU - Messenger, John C.

PY - 2014/1/1

Y1 - 2014/1/1

N2 - While drug-eluting stents have improved outcomes after percutaneous coronary intervention, 4-14% of patients in modern clinical trials still develop symptomatic restenosis. Future strategies for prevention of restenosis include modifications to the stent platform, the drug polymer or drug elution system, biocompatible stent coatings, use of bioresorbable scaffolds, and optimization of local and systemic anti-restenotic agents. Novel approaches to treating restenosis include a number of ongoing trials comparing treatment strategies with currently available drug eluting stents, use of drug coated balloons, and interventional strategies to increase stent expansion. While no single technology is likely to eliminate restenosis, the combination of these prevention and treatment strategies promises to improve the long-term outcomes of percutaneous coronary intervention.

AB - While drug-eluting stents have improved outcomes after percutaneous coronary intervention, 4-14% of patients in modern clinical trials still develop symptomatic restenosis. Future strategies for prevention of restenosis include modifications to the stent platform, the drug polymer or drug elution system, biocompatible stent coatings, use of bioresorbable scaffolds, and optimization of local and systemic anti-restenotic agents. Novel approaches to treating restenosis include a number of ongoing trials comparing treatment strategies with currently available drug eluting stents, use of drug coated balloons, and interventional strategies to increase stent expansion. While no single technology is likely to eliminate restenosis, the combination of these prevention and treatment strategies promises to improve the long-term outcomes of percutaneous coronary intervention.

UR - http://www.scopus.com/inward/record.url?scp=84958669425&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84958669425&partnerID=8YFLogxK

M3 - Chapter

AN - SCOPUS:84958669425

SN - 9781633213463

SP - 263

EP - 283

BT - Coronary Artery Restenosis: Causes, Treatment and Clinical Outcomes

PB - Nova Science Publishers, Inc.

ER -